Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on pediatric orthopedics, and its news flow reflects this specialization. Company announcements frequently cover revenue updates, financial guidance, and quarterly earnings, where OrthoPediatrics discusses performance across its trauma and deformity, scoliosis, and specialty bracing (OPSB) product lines, as well as metrics such as the number of children treated with its systems.
Readers following KIDS news can expect regular updates on financial results and outlook, including preliminary unaudited revenue releases, full quarterly earnings reports, and adjustments to annual guidance. These releases often highlight contributions from specific product categories, trends in domestic and international revenue, and management’s commentary on operational initiatives such as restructuring efforts and cost management.
OrthoPediatrics also issues news on product development and regulatory milestones. Recent examples include FDA approval of the 3P Pediatric Plating Platform Small-Mini System, additional FDA clearances within a single year, and EUMDR certification for spine, trauma, and deformity implants and instruments. The company reports on first clinical procedures with new systems, such as the VerteGlide Spinal Growth Guidance System for early onset scoliosis, and on portfolio expansions like new PediHip bracing products within OPSB.
In addition, KIDS news includes strategic and corporate updates, such as distribution partnerships (for example, with MY01 for Continuous Perfusion Sensing Technology), expansion of OPSB clinics and territories, participation in healthcare and investor conferences, and changes to the board of directors. Investors and observers who monitor this news stream gain insight into how OrthoPediatrics is evolving its pediatric orthopedic platform, broadening its product offering, and engaging with clinicians and the capital markets.
OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, has appointed Kelly Fischer to its Board of Directors effective August 8, 2025. Fischer, currently serving as Senior Vice President and CFO of Cook Medical, brings over two decades of financial and operational experience in the medical device industry.
The appointment coincides with the retirement of Terry Schlotterback, who served the company for over fifteen years as Director and Chairman of the Board. Fischer, with her background as an Audit Manager at Ernst & Young and her leadership at Cook Medical, aims to support OrthoPediatrics' strategy of market expansion and technology advancement in pediatric orthopedic care.
OrthoPediatrics (NASDAQ:KIDS) reported strong Q2 2025 financial results, achieving a record-breaking quarterly revenue of $61.1 million, up 16% year-over-year. The company demonstrated robust growth with domestic revenue increasing 17% and international revenue rising 12%. Adjusted EBITDA grew significantly by 58% to $4.1 million.
Key performance highlights include worldwide Trauma & Deformity revenue growth of 10% and Scoliosis revenue surge of 35%. The company expanded its Specialty Bracing Division with new clinics and entered Ireland, marking its first international operation. OrthoPediatrics has increased its full-year 2025 revenue guidance to $237.0-$242.0 million, projecting 16-18% growth, and expects to achieve positive free cash flow by Q4 2025.
OrthoPediatrics (NASDAQ: KIDS) announced significant expansion of its Specialty Bracing (OPSB) division through multiple new clinics and territory entries. The company has established its first California clinic in Los Angeles, opened a new facility in Dayton Children's Hospital, and expanded into the Denver, Colorado territory.
Through Acquihire opportunities, OPSB added multiple locations in New York City within major Children's Hospital centers and entered its first international market in Ireland. The Irish expansion complements OrthoPediatrics' existing implant business presence and creates opportunities for further European expansion.
OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, announced its participation in the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston, MA. The company's leadership, including CEO Dave Bailey and COO/CFO Fred Hite, will engage in a fireside chat on Wednesday, August 13, 2025, at 11:00 am ET.
Investors can access the audio webcast through OrthoPediatrics' investor relations website, with a replay available after the event.
OrthoPediatrics (NASDAQ: KIDS) has launched its new 3P™ Pediatric Plating Platform™ Hip System in the United States, successfully completing its first surgical case. The innovative system is designed to treat proximal femur fractures and deformities in pediatric patients.
The comprehensive system features a Beam Screw construct and Locking Proximal Femur Plates available in Infant, Child, and Adolescent sizes. As part of the Trauma & Deformity Correction product suite, it integrates advanced implant and instrument technology for both trauma and deformity surgeries. Following the launch, more than 10 cases have been booked for August, with expected growth in procedural volume.
OrthoPediatrics (NASDAQ: KIDS), a company specializing in pediatric orthopedics, has scheduled its second quarter 2025 financial results release for August 5, 2025 after market close. The company will host a conference call the same day at 4:30 p.m. ET to discuss the results.
Investors can access both the live event and archived webcast through the company's website at www.orthopediatrics.com in the Events & Presentations section of the Investors page. The webcast recording will remain available for at least 90 days following the event.
OrthoPediatrics (NASDAQ: KIDS) has announced a major milestone in its Global POISE (Pediatric Orthopedic Implant Safety and Efficacy) Study, with over 600 implants now being monitored across more than 300 pediatric patients.
The multi-center, post-market, prospective clinical follow-up study, launched in 2023, now includes 13 active sites across Canada, the United States, Australia, New Zealand, and South Africa. The study encompasses 17 different implant types and aims to assess the safety and efficacy of OrthoPediatrics' implant devices, focusing on implant survival and identifying device-related adverse events.
OrthoPediatrics (NASDAQ: KIDS) announced its continued role as the exclusive Emerald Sponsor for the 2025 Pediatric Orthopaedic Society of North America (POSNA) annual meeting. The company will showcase its expanding pediatric-specific solutions, including OrthoPediatrics Specialty Bracing and Enabling Technologies, across three exhibit booths. As part of its long-term commitment to POSNA, OrthoPediatrics provides support through specialty symposiums, educational grants, and scholarships for attendees.
OrthoPediatrics (NASDAQ: KIDS) has announced the expansion of its Trauma and Deformity portfolio with the 3P™ Pediatric Plating Platform™ Hip System, marking the company's 5th FDA approval in 2025. This innovative plate and screw platform aims to modernize trauma and deformity correction treatment in lower extremities.
The beta launch of 3P Hip will be followed by 3P Small/Mini in early 2026, with additional systems planned for future release. This initiative represents one of the company's largest product developments in its Trauma and Deformity division, aimed at creating the most comprehensive modern plating portfolio in pediatric orthopedic history.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
